Physician profile
Edward Kimbrough
NPI 1699756619
$15,831.20
in general payments reported to CMS, 2019-2025
52 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,331 · 2020: $1,321 · 2021: $2,822 · 2022: $2,462 · 2023: $2,462 · 2024: $2,844 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,856 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,856.39 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,753.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,897.89 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $916.01 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $833.18 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $808.17 | 2019-2024 | |
| Qol Medical, LLC | $776.93 | 2021-2025 | Sucraid, Sucraid |
| Pfizer INC. | $734.45 | 2019-2025 | |
| Ardelyx, INC. | $440.03 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $321.66 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $287.18 | 2020-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $271.82 | 2020-2024 | Linzess |
| Celgene Corporation | $255.15 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $235.46 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $225.40 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $197.35 | 2021-2024 | Dificid |
Show all 48 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kimbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.